This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
S&P Global (SPGI) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
S&P Global's (SPGI) second-quarter 2024 earnings and revenues increase year over year.
Understanding IQVIA (IQV) Reliance on International Revenue
by Zacks Equity Research
Examine the evolution of IQVIA's (IQV) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Waste Management (WM) Q2 Earnings Meet Estimates, Rise Y/Y
by Zacks Equity Research
Waste Management's (WM) second-quarter 2024 earnings and revenues rise year over year.
Top Analyst Reports for SAP, Abbott Laboratories & Citigroup
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Abbott Laboratories (ABT) and Citigroup Inc. (C), as well as two micro-cap stocks Team, Inc. (TISI) and Vaso Corporation (VASO).
Fiserv (FI) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Fiserv's (FI) second-quarter 2024 revenues and earnings increase year over year.
IQV vs. WAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
IQV vs. WAT: Which Stock Is the Better Value Option?
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Stock Market News for Jul 23, 2024
by Zacks Equity Research
U.S. stock markets closed higher on Monday after a disappointing last week.
Compared to Estimates, IQVIA (IQV) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
IQVIA (IQV) Surpasses Earnings & Revenue Estimates in Q2
by Zacks Equity Research
IQVIA's (IQV) second-quarter 2024 earnings and revenues increase year over year.
Clarivate (CLVT) to Develop Unified Library Solution for Ohio
by Subham Roy
Clarivate (CLVT) partners with OhioLINK and SearchOhio to integrate their INN-Reach platforms to develop a unified library solution for the state of Ohio.
IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 2.33% and 0.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IQVIA (IQV) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
IQVIA's (IQV) second-quarter 2024 revenues are likely to have gained from growth in the Technology and Analytics, and Research and Development segments.
Clinical Development Expertise Aids IQVIA (IQV), Costs High
by Zacks Equity Research
IQVIA (IQV) benefits from its healthcare-specific global IT infrastructure and domain expertise to expand and penetrate different markets.
Paychex (PAYX) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Paychex's (PAYX) fourth-quarter fiscal 2024 earnings and revenues are expected to have increased year over year.
EPAM Expands in Life Sciences Space With Odysseus Buyout
by Zacks Equity Research
EPAM acquires Odysseus Data Services to enhance its life sciences value chain by leveraging the latter's expertise in analytics, data methods and artificial intelligence.
IQVIA (IQV) Announces Launch of Trial Technology Platform
by Zacks Equity Research
IQVIA's (IQV) One Home for Sites allows pharmaceutical companies and their software vendors to streamline clinical application management.
Here's Why You Should Hold on to IQVIA (IQV) Stock for Now
by Zacks Equity Research
IQVIA (IQV) benefits from a powerful healthcare-specific global IT infrastructure and a robust real-world solutions ecosystem. However, high operating expenses are a headwind.
What's in Store for International Money's (IMXI) Q1 Earnings?
by Zacks Equity Research
International Money's (IMXI) revenues are likely to have benefitted from technological advancements, making transactions fast for Digital and Retail customers.
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
IQVIA (IQV) Surpasses Earnings & Revenue Estimates in Q1
by Zacks Equity Research
IQVIA's (IQV) rise in segmental revenues results in y/y top-line growth in first-quarter 2024.
IQVIA Holdings (IQV) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 2.83% and 1.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?